ArticleJournal of medicinal chemistry2026
In Vivo Efficacy and Biochemical Target Engagement of a Chromene-Based Inhibitor of Trypanosoma cruzi Lysyl-tRNA Synthetase.
Article in Journal of medicinal chemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
Abstract
Aminoacyl-tRNA synthetases (aaRSs) have emerged as essential and attractive antiparasitic targets. In Trypanosoma cruzi, in vivo evidence supporting lysyl-tRNA synthetase (LysRS) as a valid target has thus far been restricted to a single chemotype. Here, we report the repositioning of a chromene-based LysRS inhibitor developed for Plasmodium falciparum and Cryptosporidium parvum, providing an independent chemical and structural validation of LysRS in T. cruzi. Compound 5 displayed potent activity against intracellular T. cruzi amastigotes (EC50 = 0.9 μM), low host-cell toxicity, and oral efficacy in an acute murine model of Chagas disease, suppressing parasitemia and reducing tissue parasite burden. Pharmacokinetic (PK) profiling revealed favorable oral bioavailability with delayed absorption, highlighting the importance of PK context in efficacy assessment. Biochemical inhibition and crystallographic structures provide evidence of T. cruzi LysRS target engagement. These findings reinforce T. cruzi LysRS as a tractable target and reveal a new chemical scaffold for Chagas disease drug development.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.